Nano Formulations Targeting the Brain: Advances in Drug Delivery Systems for Cognitive Dysfunction in Depression | Chapter 7 | Novel Aspects on Pharmaceutical Research Vol. 8

The item focuses on various nanotechnological approaches employed to overcome the ancestry-brain obstacle (BBB) and facilitate targeted drug transmittal to the brain, that is the crux in the management of intelligent disorders. Major depressive disorder is a widespread neuropsychiatric condition that frequently goes unnoticed and undiagnosed, specifically in underserved populations lacking approach to healthcare. Studies have demonstrated that the pathophysiology of cavity involves dysfunctions in the dominant glutamatergic structure, impairments in mechanisms managing glutamate clearance and absorption, as well as morphological and maladjusted changes in brain regions guide cognitive-impassioned behaviors. Cognitive dysfunction is a prominent facet of depression, accompanying no new approved drugs for its administration since vortioxetine. Consequently, the development of nanoformulations accompanying enhanced intellect permeability, sustained action, and superior efficiency represents a hopeful future direction. This comprehensive review determines an updated summary of recent progresses in the field of nanomedicines and nano-located drug delivery systems, emphasize their potential for enhancing the efficiency of both novel and existing drugs in the situation of cognitive dysfunction in depression. Additionally, the review climaxes recent studies promoting nano-based formulations for delivering drugs guide the glutamatergic system, such as NMDA receptor modulators, neuroprotective powers, and neurotrophic factors. The potential of nanomedicines in fixing glutamate homeostasis, improving synaptic pliancy, and enhancing neurogenesis is argued. Moreover, the review discusses the advantages of nanocarrier-located strategies in improving drug pharmacokinetics, lowering side effects, and providing maintained drug release profiles, thereby permissive improved healing outcomes and patient compliance.

Author(s) Details:

Jerin James,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

Jamuna Rani,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

Sathyanarayanan Varadarajan,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

Please see the link here: https://stm.bookpi.org/NAPR-V8/article/view/11654